Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Latamoxef vs piperacillin/tazobactam for ESBL-producing Enterobacteriaceae urinary tract infection
ChiCTR2000034023Phase 4Not yet recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of latamoxef in urinary tract infection (UTI) (3 arms), sponsored by Sir Run-Run Shaw Hospital. Primary endpoints: Efficacy and Pharmacokinetic parameters. Planned start Jun 2020; status: not yet recruiting.
02
Drugs
latamoxef
03
Conditions
urinary tract infection (UTI)
Beyond the preview
Go deeper on ChiCTR2000034023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000034023.